Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 10

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 10
---
 we may not be able to obtain regulatory approval for or commercialize 
 our Program Products.                                                                                                                         |

| ● | We rely on third parties to manufacture the raw materials,                                                                                 
 including the active pharmaceutical ingredients that we use to create our therapeutic product candidate, and to manufacture the diagnostic 
 devices, including the antibodies used for testing.                                                                                        |

Risks Related to Our Intellectual Property

| ● | If we are unable to obtain and maintain effective patent                                                                                
 rights for our Product Candidates or any future product candidates, we may not be able to compete effectively in our markets. If we are 
 unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete   
 against us.                                                                                                                             |

| ● | We may not be able to protect our intellectual property rights 
 throughout the world.                                          |

| ● | We may not have sufficient patent lifespan to effectively 
 protect our products and business.                        |

| ● | If we are unable to maintain effective proprietary rights                                                            
 for our Program Products or any future product candidates, we may not be able to compete effectively in our markets. |

Risks Related to Our Business Operations

| ● | Our future success depends in part on our ability to retain                                                                  
 our senior management team, directors and other key employees and to attract, retain and motivate other qualified personnel. |

General Risk Factors We are subject to several other risks of which other public companies are subject, including without limitation, the volatility of our common stock price; our ability to comply with corporate governance laws and financial reporting standards; and our ability to maintain an effective system of internal controls.

6 RISK FACTORS The following risk factors are not exhaustive and investors are encouraged to perform their own investigation with respect to the business, prospects, financial condition and operating results of Revelation and our business, prospects, financial condition and operating results. You should carefully consider the following risk factors in addition to the other information included in this proxy statement/prospectus, including matters addressed in the section titled “Cautionary Note Regarding Forward-Looking Statements.” We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial, which may also impair our business, prospects, financial condition or operating results. The following discussion should be read in conjunction with our financial statements and notes to the financial statements included herein. Risks Related to this Offering We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. Our management will have broad discretion in